Replimune Group: Funding, Investors & Team (Sep 2026)
Replimune Group develop the next generation of ‘oncolytic immunotherapies’ for the treatment of cancer. Replimune is developing novel, proprietary products intended to improve both the direct anti-tumor effects of selective virus replication and the potency of the immune response to the tumor antigens released. The Company’s Immulytic™ platform is designed to maximize systemic immune activation, in particular to tumor neoantigens, through robust viral mediated immunogenic tumor cell killing and the delivery of optimal combinations of immune activating proteins to the tumor and draining lymph nodes. The approach is expected to be highly synergistic with immune checkpoint blockade and other approaches to cancer treatment. Replimune intends to progress these therapies rapidly through clinical trials and to combine with other immuno-oncology products with complementary mechanisms of action at an early stage.
Replimune Group has raised $665M across 4 funding rounds on record, the most recent an undisclosed round of $140M announced in Nov 2024.
That round is above the $8.0M median round size for Biotechnology companies tracked on FundedIQ over the last two years.
Replimune Group Company Profile and Key Stats
Latest funding round on record: Nov 2024.
Replimune Group Funding Rounds
Replimune Group raised $200M in a Post-IPO Debt announced in Oct 2022.
2 months later, an undisclosed round of $225M was announced in Dec 2022.
1.5 years later, an undisclosed round of $100M was announced in Jun 2024.
5 months later, an undisclosed round of $140M was announced in Nov 2024.
Replimune Group Founders and Leadership Team
Contact details for the Replimune Group team: 2 of 2 have an email address on file.
Start 14-day free trial →Replimune Group Funding Compared to Other Biotechnology Startups
Replimune Group's latest round of $140M is above the median round in Biotechnology. Medians cover the last 24 months of disclosed rounds.
Funded Startups Like Replimune Group in Biotechnology and Woburn
Companies Similar to Replimune Group
Noveome Biotherapeutics, Inc. is an advanced biopharmaceutical company that focuses on groundbreaking…
XiltriX North America is an information technology company that specializes in monitoring, predictive…
Novir is an emerging diagnostic biotechnology company with an unmatched team of professionals and trusted…
Abcuro’s mission is to develop a new class of immune-modulatory bio-therapeutics for treating both…
Georgiamune Inc. is a privately-owned biotechnology company that specializes in advanced immunotherapy…
Bridge to Life was founded with the mission of improving organ transplants by licensing and developing new…
InduPro is a biotechnology firm that focuses on protein therapeutics and technologies related to cell-surface…
Paterna BioSciences, Inc. is a pioneering biotechnology company dedicated to solving the significant…
Legendary Bio's solidarity is a determined spotlight on introducing another period of quality guideline.
Cataract surgery is the single most common procedure performed in the United States annually. Despite…
InSitu Biologics is a developer of a drug delivery platform designed to focus on development of new and…
Remedium Bio is a gene therapy company in the Boston area that is dedicated to developing cures for severe…
Replimune Group Funding FAQs
What does Replimune Group do?
Replimune Group develop the next generation of ‘oncolytic immunotherapies’ for the treatment of cancer. Replimune is developing novel, proprietary products intended to improve both the direct anti-tumor effects of selective virus replication and the potency of the immune response to the tumor antigens released. The Company’s Immulytic™ platform is designed to maximize systemic immune activation, in particular to tumor neoantigens, through robust viral mediated immunogenic tumor cell killing and the delivery of optimal combinations of immune activating proteins to the tumor and draining lymph nodes. The approach is expected to be highly synergistic with immune checkpoint blockade and other approaches to cancer treatment. Replimune intends to progress these therapies rapidly through clinical trials and to combine with other immuno-oncology products with complementary mechanisms of action at an early stage.
How much funding has Replimune Group raised?
Replimune Group has raised $665M across 4 rounds on record. The most recent is an undisclosed round of $140M announced in Nov 2024.
When did Replimune Group last raise funding?
Replimune Group's most recent funding round on record is an undisclosed round of $140M, announced in Nov 2024.
Who founded Replimune Group?
FundedIQ lists Philip Sparke (Founder), Robert Coffin (Founder) at Replimune Group.
Where is Replimune Group headquartered?
Replimune Group is based in Woburn, Massachusetts, United States.
How many employees does Replimune Group have?
Replimune Group is in the 101-250 employee band.
How does Replimune Group's funding compare to other Biotechnology startups?
Replimune Group's latest round of $140M is above the $8.0M median round size for Biotechnology companies on FundedIQ across 4,179 tracked companies over the last two years.
About FundedIQ's Replimune Group Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for Replimune Group is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Every newly funded startup with its round, its investors and its founders: delivered weekly by email, or searchable in the app.
Alerts from $19/mo · Pro from $99/mo. Card required, nothing charged until day 15, and we email you 3 days before that.